ENHANCE (Elevated NKG2A and HLA-E Amplify NK/CD8 Checkpoint Engagers): A Phase 2 Trial of Durvalumab (MEDI4736) plus Monalizumab in Non-Muscle-Invasive Bladder Cancer

The purpose of this study is to find out if researchers can lower the chance of non-muscle invasive bladder cancer growing or spreading by using a combination of drugs called durvalumab and monalizumab.